

Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017

<https://marketpublishers.com/r/H62C8DB5837EN.html>

Date: June 2017

Pages: 30

Price: US\$ 3,500.00 (Single User License)

ID: H62C8DB5837EN

Abstracts

Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017

SUMMARY

According to the recently published report 'Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017'; Human Papillomavirus Minor Capsid Protein L2 (L2) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Human Papillomavirus Minor Capsid Protein L2 (L2) - L2 is a minor capsid component and lacks the capacity to form VLPs. This protein plays a role in capsid stabilization through interaction with the major capsid protein L1. It also plays a role through its interaction with host dynein in the intracellular microtubule-dependent transport of viral capsid toward the nucleus. It mediates the viral genome import into the nucleus through binding to host importins.

The report 'Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017' outlays comprehensive information on the Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews also reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 4 respectively. Similarly, the universities portfolio in Preclinical

stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Cervical Cancer, Human Papillomavirus (HPV) Associated Cancer, Human Papillomavirus Infections, Genital Warts (Condylomata Acuminata) and Warts.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Minor Capsid Protein L2 (L2)

The report reviews Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics and enlists all their major and minor projects

The report assesses Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Human Papillomavirus Minor Capsid Protein L2 (L2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Papillomavirus Minor Capsid Protein L2 (L2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Human Papillomavirus Minor Capsid Protein L2 (L2) - Overview

Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Human Papillomavirus Minor Capsid Protein L2 (L2) - Companies Involved in
Therapeutics Development

Agilvax Inc

Cancer Research Technology Ltd

Pathovax LLC

Human Papillomavirus Minor Capsid Protein L2 (L2) - Drug Profiles

AX-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TA-CIN - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Human Papillomavirus Minor Capsid Protein L2 (L2) - Dormant Products

Human Papillomavirus Minor Capsid Protein L2 (L2) - Product Development Milestones

Featured News & Press Releases

Oct 27, 2016: PathoVax Wins \$500,000 in 43North Contest

Sep 06, 2016: Agilvax Receives New Patent for Its Cost-Effective Broadly Protective HPV Vaccine Candidate

Feb 03, 2015: Agilvax Is Advancing Clinical Production of its Lead Vaccine Against Human Papillomavirus

Oct 30, 2014: National Cancer Institute supports next-generation Austrian HPV vaccine

Sep 10, 2013: New, Even More Effective HPV Vaccine In Sight

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Agilvax Inc, H1 2017
Pipeline by Cancer Research Technology Ltd, H1 2017
Pipeline by Pathovax LLC, H1 2017
Dormant Projects, H1 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

Agilvax Inc

Cancer Research Technology Ltd

Pathovax LLC

I would like to order

Product name: Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017

Product link: <https://marketpublishers.com/r/H62C8DB5837EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H62C8DB5837EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970